REG - Goldman Sachs AM LP Avadel Pharma plc - Form 8.1b-Avadel Pharmaceuticals plc

Goldman SachsAnnouncement

14/01/2026 08:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260114:nRSN8522Oa&default-theme=true

RNS Number : 8522O  Goldman Sachs Asset Management LP  14 January 2026

 
FORM 8.1(b)(ii)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1(b)(ii) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT FUND MANAGERS ON BEHALF OF DISCRETIONARY CLIENTS

 

1. KEY INFORMATION

 

 Name of exempt fund manager                                              (GS) GOLDMAN SACHS ASSET MANAGEMENT, L.P.
 Company dealt in                                                         AVADEL PHARMACEUTICALS PLC
 Class of relevant security to which the dealings being disclosed relate  USD 0.01 ordinary shares
 (Note1)
 Date of dealing                                                          12 January 2026

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in  (Note 2)

 

                                              Long             Short
                                              Number   (%)     Number  (%)
 (1) Relevant securities                      180,688  (0.18)  0       (0.00)
 (2) Derivatives (other than options)         0        (0.00)  0       (0.00)
 (3) Options and agreements to purchase/sell  0        (0.00)  0       (0.00)
 Total                                        180,688  (0.18)  0       (0.00)

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in  (Note 2)

 

 Class of relevant security:                  Long         Short
                                              Number  (%)  Number  (%)
 (1) Relevant securities
 (2) Derivatives (other than options)
 (3) Options and agreements to purchase/sell
 Total

 

3.    DEALINGS (Note 3)

(a) Purchases and sales

 

 Purchase/sale  Number of relevant securities  Price per unit  (Note 4)
 Sale           20                             21.5000 USD

 

(b) Derivatives transactions (other than options transactions)

 

 Product name, e.g. CFD  Nature of transaction  (Note 5)   Number of relevant securities  (Note 6)   Price per unit  (Note 4)

 

(c) Options transactions in respect of existing relevant securities

 

(i) Writing, selling, purchasing or varying

 

 Product name,e.g. call option  Writing, selling,  purchasing, varying etc.   Number of securities to which the option relates  (Note 6)   Exercise price  Type, e.g. American, European etc.  Expiry date  Option money paid/received per unit  (Note 4)

 

(ii)            Exercising

 

 Product name,e.g. call option  Number of securities  Exercise price per unit  (Note 4)

 

(d)            Other dealings (including transactions in respect of new securities)  (Note 3)

 

 Nature of transaction  (Note 6)   Details  Price per unit (if applicable)  (Note 4)

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 Full details of any agreement, arrangement or understanding between the person
 disclosing and any other person relating to the voting rights of any relevant
 securities under any option referred to on this form or relating to the voting
 rights or future acquisition or disposal of any relevant securities to which
 any derivative referred to on this form is referenced.  If none, this should
 be stated.
 NONE

 

Is a Supplemental Form 8 attached? (Note 9)        NO

 

 Date of disclosure                            14 January 2026
 Contact name                                  Papa Lette and Andrzej Szyszka
 Telephone number                              +33(1) 4212 1459 / +48(22) 317 4817
 Name of offeree/offeror with which connected  AVADEL PHARMACEUTICALS PLC
 Nature of connection (Note 9)                 Advisor to Offeree

 

Notes

1. See the definition of relevant securities in Rule 2.1 of Part A of the
Rules.

2. See the definition of interest in a relevant security in Rule 2.6 of Part A
of the Rules and see Rule 8.6(a) of Part B of the Rules.

If an option over new securities is acquired or exercised, the relevant
interest should be disclosed under (1) Relevant securities If an option over
existing relevant securities is acquired or exercised, the relevant interest
should be disclosed under (3) Options and agreements to purchase/sell.

3. See the definition of a dealing in Rule 2.1 of Part A of the Rules.

4. For all prices and other monetary amounts, the currency must be stated.

5. If a long position has been increased or decreased as a result of the
dealing, write an increased long or a decreased long respectively. If a short
position has been increased or decreased as a result of the dealing, write an
increased short or a decreased short respectively. If the dealing has not
resulted in a long or short position being increased or reduced, give details
of the variation or other dealing.

6. See Rule 2.6(d) of Part A of the Rules.

7. State type of dealing, e.g. subscription, conversion, exercise etc.

8. Where there are open option positions or open derivative positions (other
than CFDs), or where there is an agreement to purchase or to sell,
Supplemental Form 8 must be completed.

9. See the definition of a connected fund manager in Rule 2.2 of Part A of the
Rules.

For full details of disclosure requirements, see Rule 8 of the Rules. If in
doubt, consult the Panel.

References in these notes to the Rules are to the Irish Takeover Panel Act,
1997, Takeover Rules, 2013

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPDZLBFQFLLBBE



            Copyright 2019 Regulatory News Service, all rights reserved